301207 Hualan Biological Vaccine Inc.
- 19.49
- +0.21+1.09%
Hualan Biological Vaccine Inc. News
Hualan Vaccine: Report for the third quarter of 2024
Hualan Vaccine (301207.SZ) released its performance for the first three quarters, with a net income of 0.267 billion yuan, a decrease of 57.54%.
Hualan Vaccine (301207.SZ) released the third quarter report for 2024, with the company's revenue for the first three quarters at 9...
Hualan Vaccine (301207.SZ): Net income in the first three quarters was 0.267 billion yuan, a year-on-year decrease of 57.54%.
Galenghui October 29th | Hualan Vaccine (301207.SZ) announced the third quarter report of 2024, with the company's revenue reaching 0.957 billion yuan in the first three quarters, a year-on-year decrease of 44.28%; the net income attributable to the company's shareholders was 0.267 billion yuan, a year-on-year decrease of 57.54%; the net income attributable to the company's shareholders excluding non-recurring gains and losses was 0.196 billion yuan, a year-on-year decrease of 64.65%; the basic earnings per share was 0.4463 yuan.
Hualan Vaccine (301207.SZ): Currently, there is no cooperation with foreign giants companies.
On September 20th, Gelonghui announced that Hualan Vaccine (301207.SZ) has consistently adhered to independent research and development, as well as the combination of industry, academia, and research, and has collaborated with domestic high-level universities, research institutes, and other institutions to carry out a series of cooperative research and development work. Currently, there is no collaboration with foreign giants.
HL VACCINE (301207.SZ): Among the vaccines currently in the registration process, there is still no vaccine with antibodies against monkeypox.
On September 20th, Geelong reported that Hualan Vaccine (301207.SZ) stated on the investor interaction platform that among the vaccines under registration procedure, there is currently no vaccine with antibodies against smallpox. The company will continue to focus on cutting-edge categories of vaccines and steadily promote the research and development of products under development.
Hualan Vaccine (301207) Interim Report Review: Performance under pressure, waiting for the sales of flu vaccines to pick up.
Investment Highlights: The company, founded in 2005, went public on the Shenzhen GEM in 2022. It is a high-tech enterprise specialized in the research, production, and sales of human vaccines. Currently, the company has obtained drug registration certificates for its vaccines.
Express News | The overall performance of vaccine companies in the first half of the year was "bleak".
Hualan Vaccine (301207.SZ): cumulative repurchased 0.93% of shares
On September 2, Geelong reported that as of August 31, 2024, the company has repurchased a total of 5,600,767 shares through the Shenzhen Stock Exchange trading system through centralized bidding trading, accounting for 0.93% of the company's current total share capital. The highest transaction price was 18.52 yuan/share, the lowest transaction price was 16.23 yuan/share, and the total transaction amount was 99.1311 million yuan (excluding transaction costs). The implementation of the repurchase meets the requirements of relevant laws and regulations and complies with the company's established repurchase plan.
Hualan Vaccine (301207): Leading in issuing batches continuously, waiting quietly for a surge in flu vaccines.
Performance Review On August 29, 2024, the company released its 2024 interim report. In the first half of 2024, the company achieved revenue of 0.036 billion yuan, a year-on-year decrease of 76%. It also achieved a net income attributable to shareholders of 0.025 billion yuan.
Hualan Vaccine (301207): Performance in the first half of the year is normal, waiting for sales in the second half of the year.
1H24 revenue, net profit attributable to the parent company's announcement 1H24 revenue, net profit attributable to the parent, non-net profit 0.036/0.025/-0.021 billion yuan (-76%/-76%/-136% yoy),
Hualan Vaccine: 2024 Semi-Annual Report
Hualan Vaccine: 2024 Semi-Annual Report Summary
Hualan Vaccine (301207.SZ): The net income in the first half of the year was 25.2744 million yuan, a year-on-year decrease of 76.65%.
On August 29th, Gelonhui announced its semi-annual report for 2024, with reported revenue of 35.529 million yuan, a year-on-year decrease of 76.25%; net income attributable to shareholders of listed companies was 25.2744 million yuan, a year-on-year decrease of 76.65%; net income attributable to shareholders of listed companies after deducting non-recurring gains and losses was -21.3215 million yuan; basic earnings per share was 0.0421 yuan.
Huawei Health Vaccine (301207.SZ) released its semi-annual performance, with a net income of 25.2744 million yuan, a year-on-year decrease of 76.65%.
Hualan Vaccine (301207.SZ) released its semi-annual report for 2024, during which the company achieved revenue of 3...
Express News | Hualan Vaccine: Net income in the first half of the year decreased by 76.65% year-on-year.
Express News | Hualan Vaccine responded to today's limit up: There is a shortage of flu vaccines, which is bullish for other vaccine companies.
Express News | Hualan Vaccine: The company's flu vaccine does not have a problem with reduced efficacy, and the production volume can meet market demand.
A-share vaccine stocks rise, Zhonglan vaccine up more than 10%.
Gelonghui August 27th | Hualan Vaccine, Jindike rose more than 10%, Shenzhou Cell, Baike Biotech, shandong lukang pharmaceutical and others surged. On the news front, Sanofi has temporarily suspended the supply and sales of flu vaccines in the country.
Express News | Vaccine stocks surged, with Hualan Vaccine rising more than 10%.
Hualan Vaccine (301207.SZ): has repurchased 0.55% of the shares.
On August 2nd, Gelon Hui announced that as of July 31st, 2024, the company has repurchased 3,320,100 shares of stock through the Shenzhen Stock Exchange trading system through centralized bidding trading, accounting for 0.55% of the company's current total share capital. The highest fill price was 18.13 yuan/share and the lowest fill price was 16.23 yuan/share, with a total transaction amount of 57.5927 million yuan (excluding trading fees). The implementation of the repurchase meets the requirements of relevant laws and regulations and complies with the company's established repurchase plan.
Analysis
Price Target
No Data
No Data